Aplastic Anemia - Pipeline Review, H1 2016

Publication ID: GMD0516162
Publication Date: May 31, 2016
Pages: 81
Publisher: Global Markets Direct
Countries: Global [1]

$2,000.00

Publication License Type *

- SINGLE USER LICENSE (PDF), $2,000.00
- SITE LICENSE (PDF), $4,000.00
- GLOBAL LICENSE (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Description:

Aplastic Anemia - Pipeline Review, H1 2016

Summary


The report provides comprehensive information on the therapeutics under development for Aplastic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and
relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Aplastic Anemia
- The report reviews pipeline therapeutics for Aplastic Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Aplastic Anemia therapeutics and enlists all their major and minor projects
- The report assesses Aplastic Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Aplastic Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Aplastic Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aplastic Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents:

Table of Contents
Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
Nov 17, 2015: Regen BioPharma Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology’s Annual Meeting
Sep 25, 2015: Regen BioPharma Announces Positive Results from GLP Safety Study for HemaXellerate
Sep 10, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Treatment for Hypoplastic Myelodysplastic Syndrome and Aplastic Anemia
Sep 02, 2015: Novartis receives EU approval for new Revolade use as first-in-class therapy for patients with severe aplastic anemia
Jul 24, 2015: Novartis drug Revolade recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Aplastic Anemia, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Aplastic Anemia - Pipeline by 3SBio Inc., H1 2016
Aplastic Anemia - Pipeline by Acceleron Pharma, Inc., H1 2016
Aplastic Anemia - Pipeline by Amgen Inc., H1 2016
Aplastic Anemia - Pipeline by BioLineRx, Ltd., H1 2016
Aplastic Anemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Aplastic Anemia - Pipeline by Novartis AG, H1 2016
Aplastic Anemia - Pipeline by Pluristem Therapeutics Inc., H1 2016
Aplastic Anemia - Pipeline by Regen BioPharma, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Aplastic Anemia Therapeutics - Recent Pipeline Updates, H1 2016 48
Aplastic Anemia - Dormant Projects, H1 2016 71
Aplastic Anemia - Discontinued Products, H1 2016 72

List of Figures
Number of Products under Development for Aplastic Anemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Targets, H1 2016 22
Number of Products by Stage and Targets, H1 2016 22
Number of Products by Mechanism of Actions, H1 2016 24
Number of Products by Stage and Mechanism of Actions, H1 2016 24
Number of Products by Routes of Administration, H1 2016 26
Number of Products by Stage and Routes of Administration, H1 2016 26
Number of Products by Molecule Types, H1 2016 28
Number of Products by Stage and Molecule Types, H1 2016 28

Companies Mentioned:

3SBio Inc.
Acceleron Pharma, Inc.
Amgen Inc.
BioLineRx, Ltd.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pluristem Therapeutics Inc.
Regen BioPharma, Inc.

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every
person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

---

**Source URL:** https://www.marketresearchreports.com/global-markets-direct/aplastic-anemia-pipeline-review-h1-2016

**Links**